RaySearch Laboratories AB (publ) risk profile
22 Normal where most of the sector sits
Measured 21 October 2026 from RAY-B's filed statements. Recomputed nightly.
22 (Normal), driven by Market expectation at 52, over 5 weighted categories on the SOFTWARE profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 52 | Elevated | Volatile | One-year price volatility — 49.1% |
| Operating pressure | 2 | Contained | Easing | Costs outgrowing revenue — -11.9 percentage points |
| Cash conversion | 8 | Contained | Stable | Capital spending against operating cash — 0.03x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 23 | Normal | Stable | R&D-intensity gap against peers — -4.5 percentage points |
| Concentration | 24 | Normal | Stable | Geographic concentration — 1,968 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for RaySearch Laboratories AB (publ)